Skip to main content

Advertisement

SpringerLink
Log in

Malignant Pleural Mesothelioma

  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Malignant pleural mesothelioma (MPM) is a relatively rare thoracic malignancy accounting for about 2000–3000 new cases per year. This cancer has been increasing in incidence and is strongly associated with asbestos exposure. Also, it is characterized by insidious growth and clinical presentation at an advanced stage of disease. In the past, the treatment of this disease was limited to marginally effective chemotherapy and morbid surgery. This review explores the clinical presentation of MPM, its diagnostic approach and the relevant and recent studies that define the role of chemotherapy, radiation, and various surgical options. Currently, even with aggressive surgical interventions and multimodality strategies, cure remains elusive, although life prolongation has been achieved. Additionally, promising new therapies and interventions that are currently being studied are introduced in this review.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Yang H, Testa JR, Carbone M. Mesothelioma epidemiology, carcinogenesis, and pathogenesis. Curr Treat Options Oncol. 2008;9(2–3):147–57.

    Article  PubMed  Google Scholar 

  2. Milne JE. Thirty-two cases of mesothelioma in Victoria, Australia: a retrospective survey related to occupational asbestos exposure. Br J Ind Med. 1976;33(2):115–22.

    PubMed  CAS  Google Scholar 

  3. Greenberg M, Davies TA. Mesothelioma register 1967–68. Br J Ind Med. 1974;31(2):91–104.

    PubMed  CAS  Google Scholar 

  4. Chirieac LR, Corson JM. Pathologic evaluation of malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg. 2009;21(2):121–4.

    Article  PubMed  Google Scholar 

  5. Belli C, Anand S, Tassi G, Fennell D, Mutti L. Translational therapies for malignant pleural mesothelioma. Expert Rev Respir Med. 2010;4(2):249–60.

    Article  PubMed  Google Scholar 

  6. Ruffie P, Feld R, Minkin S, et al. Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients. J Clin Oncol. 1989;7(8):1157–68.

    PubMed  CAS  Google Scholar 

  7. Lee ST, Ghanem M, Herbertson RA, et al. Prognostic value of 18F-FDG PET/CT in patients with malignant pleural mesothelioma. Mol Imag Biol. 2009;11(6):473–9.

    Article  CAS  Google Scholar 

  8. Flores RM, Akhurst T, Gonen M, Larson SM, Rusch VW. Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2003;126(1):11–6.

    Article  PubMed  Google Scholar 

  9. Edge SB, American Joint Committee on Cancer. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.

    Google Scholar 

  10. Schouwink JH, Kool LS, Rutgers EJ, et al. The value of chest computer tomography and cervical mediastinoscopy in the preoperative assessment of patients with malignant pleural mesothelioma. Ann Thorac Surg. 2003;75(6):1715–8. discussion 1718–1719.

    Article  PubMed  Google Scholar 

  11. Erasmus JJ, Truong MT, Smythe WR, et al. Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: staging implications. J Thorac Cardiovasc Surg. 2005;129(6):1364–70.

    Article  PubMed  Google Scholar 

  12. Rice DC, Erasmus JJ, Stevens CW, et al. Extended surgical staging for potentially resectable malignant pleural mesothelioma. Ann Thorac Surg. 2005;80(6):1988–92. discussion 1992–1983.

    Article  PubMed  Google Scholar 

  13. Schneider DB, Clary-Macy C, Challa S, et al. Positron emission tomography with f18-fluorodeoxyglucose in the staging and preoperative evaluation of malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2000;120(1):128–33.

    Article  PubMed  CAS  Google Scholar 

  14. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636–44.

    Article  PubMed  CAS  Google Scholar 

  15. Dougherty TJ, Gomer CJ, Henderson BW, et al. Photodynamic therapy. J Natl Cancer Inst. 1998;90(12):889–905.

    Article  PubMed  CAS  Google Scholar 

  16. Friedberg JS. Photodynamic therapy as an innovative treatment for malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg. 2009;21(2):177–87.

    Article  PubMed  Google Scholar 

  17. •Wolf AS, Daniel J, Sugarbaker DJ. Surgical techniques for multimodality treatment of malignant pleural mesothelioma: extrapleural pneumonectomy and pleurectomy/decortication. Semin Thorac Cardiovasc Surg. Summer 2009;21(2):132–148. This article clearly explains the technical nuances of performing extrapleural pneumonectomies and pleurectomy/decortication.

    Article  PubMed  Google Scholar 

  18. ••Flores RM, Pass HI, Seshan VE, et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg. 2008;135(3):620–626, 626 e621-623. This study showed that both extrapleural pneumonectomies and pleurectomy/decortication have comparable outcomes for the treatment of mesothelioma.

  19. Sugarbaker DJ, Jaklitsch MT, Bueno R, et al. Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies. J Thorac Cardiovasc Surg. 2004;128(1):138–46.

    Article  PubMed  Google Scholar 

  20. Soysal O, Karaoglanoglu N, Demiracan S, et al. Pleurectomy/decortication for palliation in malignant pleural mesothelioma: results of surgery. Eur J Cardiothorac Surg. 1997;11(2):210–3.

    Article  PubMed  CAS  Google Scholar 

  21. Balduyck B, Trousse D, Nakas A, Martin-Ucar AE, Edwards J, Waller DA. Therapeutic surgery for nonepithelioid malignant pleural mesothelioma: is it really worthwhile? Ann Thorac Surg. 2010;89(3):907–11.

    Article  PubMed  Google Scholar 

  22. Sugarbaker DJ, Flores RM, Jaklitsch MT, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg. 1999;117(1):54–63. discussion 63–55.

    Article  PubMed  CAS  Google Scholar 

  23. Ceresoli GL, Locati LD, Ferreri AJ, et al. Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma. Lung Cancer. 2001;34(2):279–87.

    Article  PubMed  CAS  Google Scholar 

  24. Neragi-Miandoab S, Richards WG, Sugarbaker DJ. Morbidity, mortality, mean survival, and the impact of histology on survival after pleurectomy in 64 patients with malignant pleural mesothelioma. Int J Surg. 2008;6(4):293–7.

    Article  PubMed  Google Scholar 

  25. Zellos L, Richards WG, Capalbo L, et al. A phase I study of extrapleural pneumonectomy and intracavitary intraoperative hyperthermic cisplatin with amifostine cytoprotection for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2009;137(2):453–8.

    Article  PubMed  Google Scholar 

  26. Tilleman TR, Richards WG, Zellos L, et al. Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study. J Thorac Cardiovasc Surg. 2009;138(2):405–11.

    Article  PubMed  Google Scholar 

  27. Richards WG, Zellos L, Bueno R, et al. Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma. J Clin Oncol. 2006;24(10):1561–7.

    Article  PubMed  CAS  Google Scholar 

  28. Rusch V, Saltz L, Venkatraman E, et al. A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma. J Clin Oncol. 1994;12(6):1156–63.

    PubMed  CAS  Google Scholar 

  29. Lee JD, Perez S, Wang HJ, Figlin RA, Holmes EC. Intrapleural chemotherapy for patients with incompletely resected malignant mesothelioma: the UCLA experience. J Surg Oncol. 1995;60(4):262–7.

    Article  PubMed  CAS  Google Scholar 

  30. van Ruth S, Baas P, Haas RL, Rutgers EJ, Verwaal VJ, Zoetmulder FA. Cytoreductive surgery combined with intraoperative hyperthermic intrathoracic chemotherapy for stage I malignant pleural mesothelioma. Ann Surg Oncol. 2003;10(2):176–82.

    Article  PubMed  Google Scholar 

  31. Kotsakis A, Georgoulias V. Targeting epidermal growth factor receptor in the treatment of non-small-cell lung cancer. Expert Opin Pharmacother. 2010;11(14):2363–89.

    Article  PubMed  CAS  Google Scholar 

  32. Govindan R, Kratzke RA, Herndon 2nd JE, et al. Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Cancer Res. 2005;11(6):2300–4.

    Article  PubMed  CAS  Google Scholar 

  33. Garland LL, Rankin C, Gandara DR, et al. Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. J Clin Oncol. 2007;25(17):2406–13.

    Article  PubMed  CAS  Google Scholar 

  34. Leigh RA, Webster I. Lymphocytic infiltration of pleural mesothelioma and its significance for survival. S Afr Med J. 1982;61(26):1007–9.

    PubMed  CAS  Google Scholar 

  35. Gregoire M. What’s the place of immunotherapy in malignant mesothelioma treatments? Cell Adhes Migrat. 2010;4(1):153–61.

    Article  Google Scholar 

  36. Aelony Y, Yao JF. Prolonged survival after talc poudrage for malignant pleural mesothelioma: case series. Respirology. 2005;10(5):649–55.

    Article  PubMed  Google Scholar 

  37. Ak G, Metintas M, Yildirim H, et al. Pleurodesis in follow-up and treatment of malignant pleural mesothelioma patients. Tüberk Toraks. 2009;57(1):22–31.

    PubMed  Google Scholar 

  38. Murthy SC, Okereke I, Mason DP, Rice TW. A simple solution for complicated pleural effusions. J Thorac Oncol. 2006;1(7):697–700.

    Article  PubMed  Google Scholar 

  39. Tremblay A, Michaud G. Single-center experience with 250 tunnelled pleural catheter insertions for malignant pleural effusion. Chest. 2006;129(2):362–8.

    Article  PubMed  Google Scholar 

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Department of Cardiothoracic Surgery, Cleveland Clinic Foundation, J4-1, 9500 Euclid Avenue, Cleveland, OH, 44195, USA

    Siva Raja, Sudish C. Murthy & David P. Mason

Authors
  1. Siva Raja
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sudish C. Murthy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David P. Mason
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David P. Mason.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Raja, S., Murthy, S.C. & Mason, D.P. Malignant Pleural Mesothelioma. Curr Oncol Rep 13, 259–264 (2011). https://doi.org/10.1007/s11912-011-0177-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-011-0177-9

Keywords

Search

Navigation